Janus Henderson Group PLC Has $362.17 Million Holdings in Lantheus Holdings, Inc. $LNTH

Janus Henderson Group PLC decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.3% in the 1st quarter, Holdings Channel reports. The fund owned 4,774,841 shares of the medical equipment provider’s stock after selling 932,406 shares during the quarter. Janus Henderson Group PLC owned 0.07% of Lantheus worth $362,172,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its stake in Lantheus by 157.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,396 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 853 shares during the period. California State Teachers Retirement System raised its stake in shares of Lantheus by 22.3% in the 1st quarter. California State Teachers Retirement System now owns 78,207 shares of the medical equipment provider’s stock valued at $5,932,000 after purchasing an additional 14,239 shares during the period. Empowered Funds LLC acquired a new stake in shares of Lantheus in the 1st quarter valued at about $909,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Lantheus by 4.4% in the first quarter. The Manufacturers Life Insurance Company now owns 69,181 shares of the medical equipment provider’s stock valued at $5,247,000 after purchasing an additional 2,911 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in shares of Lantheus by 58.4% in the first quarter. Quantinno Capital Management LP now owns 9,772 shares of the medical equipment provider’s stock valued at $741,000 after purchasing an additional 3,601 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Trading Up 1.0%

Shares of NASDAQ:LNTH opened at $101.00 on Friday. The company’s 50-day moving average price is $104.06 and its two-hundred day moving average price is $86.65. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The stock has a market capitalization of $6.58 billion, a PE ratio of 24.34 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.Lantheus’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on LNTH shares. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a report on Wednesday. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Truist Financial lifted their price objective on shares of Lantheus from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $109.71.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.